Cellular Senescence is a Common Characteristic Shared by Preneoplasic and Osteo-Arthritic Tissue by Brondello, Jean-Marc et al.
10  The Open Rheumatology Journal, 2010, 4, 10-14   
 
  1874-3129/10  2010 Bentham Open 
Open Access 
Cellular Senescence is a Common Characteristic Shared by Preneoplasic 
and Osteo-Arthritic Tissue 
Jean-Marc Brondello
*,1, Didier Philipot
1, Farida Djouad
1, Christian Jorgensen
1,2,3 and Danièle Noël
1 
1Inserm, U844, Montpellier, F-34295, France 
2Université MONTPELLIER 1, UFR de Médecine, Montpellier, F-34000, France 
3Immuno-Rheumatology Department, Lapeyronie Hospital, Montpellier, F-34295, France 
Abstract: Objective: This study aims at highlighting the common signature between cartilaginous tissue in osteoarthritis 
(OA) and preneoplasic tissues preceding neoplasia and tumour formation and, second, focusing on the molecular 
mechanisms at the aetiology of both pathologies. 
Results: Because age is the highest risk factor common for both OA and cancer development, it is tempting to compare the 
molecular mechanisms occurring at the onset of OA and preneoplasic lesions. Indeed, cellular senescence seems to be a 
common characteristic. Cellular senescence represents a natural barrier to suppress the unscheduled proliferation of 
damaged cells acting as a strong tumour suppressor pathway and in OA, it also occurs prematurely in chondrocytes. In 
this study, we review a number of molecular factors associated with the senescent phenotype. 
Conclusion: Whereas accumulation of senescent cells in preneoplasic-like lesions leads to tissue degeneration and 
potentially tumour development; in OA, senescent cells accumulate in a slowly proliferative tissue. This is likely 
contributing at reducing the risk of cell transformation. 
Keywords: Senescence, aging, chondrocytes, osteoarthritis, neoplasia. 
INTRODUCTION 
  Osteoarthritis (OA) is a chronic degenerative disease 
characterized by progressive cartilage erosion leading to 
pain. At present, there is no efficient treatment to cure or 
even delay the progression of this most common disability-
associated disease. The aetiology of OA is still unknown 
although clinical studies have shown that numerous factors 
are strong determinants. Among them, can be included 
genetic predisposition, obesity and primarily, age [1]. 
Remarkably, all of these factors are also associated with the 
prevalence of other age-related human diseases such as 
atherosclerosis [2] and preneoplasic lesions [3]. Recent 
works have focussed on the molecular events that govern the 
genesis of these lesions accumulating with age in numerous 
tissues [4, 5]. Preneoplasic lesions are benign. Nevertheless 
these cells may acquire, with time, new properties, such as 
genetic instability inducing in fine cellular transformation 
leading to neoplasia and eventually tumour formation. In 
summary, preneoplasic lesions are seen as natural barriers 
preventing tumour expansion and malignancy. Analysis of 
these recent studies reveals the strikingly high number of 
common characteristics between preneoplasic tissues and 
OA cartilage. Even if these common characteristics of 
cellular senescence in both pathologies may be merely co-
incidental, they have to be highlighted in the prospect of   
 
 
*Address correspondence to this author at the Inserm U844, Hôpital Saint 
Eloi, Bâtiment INM, 80 Avenue Augustin Fliche, Montpellier, F-34295, 
France; Tel: 33 (0) 4 99 63 60 92; Fax: 33 (0) 4 99 63 60 20;  
E-mail: jean-marc.brondello@inserm.fr 
using new therapeutic intervention in OA. Thus, the aim of 
this review is first, to highlight their common signatures and 
second, to focus on the molecular mechanisms shared by 
both pathologies. 
ARTICULAR CARTILAGE BIOLOGY 
  The role of articular cartilage is to transmit forces across 
diarhodial joints and maintain a friction-free surface at the 
epiphyseal ends of long bones to support limb movement. 
Articular cartilage is organised in various layers and contains 
one cell component, the chondrocyte which contributes by 
its anabolic function to the production and/or maintenance of 
the extracellular matrix (ECM) of the tissue [6]. The ECM is 
composed of a network of collagen fibres, primarily type II 
collagen and secondarily, type IX and XI collagens that give 
the tissue its shape, strength and tensile force. It also 
contains a highly hydrated gel of large proteoglycans, 
aggrecan being the most prominent, and glycoproteins which 
give resistance to compression [7]. Once the cartilage is 
formed in the adult, the turn-over of ECM components is 
very low. 
OA PHYSIOPATHOLOGY 
  Among the numerous diseases which affect cartilage, OA 
is the most prevalent one. A number of studies have 
described the progression of this common disease [8]. The 
first detectable changes during OA by clinical examination 
are softening, fibrillation and ulceration of the cartilage. At 
latest stages of the disease, appearance of chondrophytes 
from neodifferentiated periosteal cells which eventually turn 
after calcification into osteophytes are present on the joint  
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edge [9]. These osteophytes, as a sort of extension of the 
articular surface, are responsible of the increasing pain. 
Finally, subchondral bone remodelling is proposed to be one 
driving force that accelerates cartilage [10]. 
  Chondrocytes are the central players in the changes that 
occur during primary or secondary OA [8]. Anabolic 
function of chondrocytes is decreasing following pathology 
progression. This loss of function is mainly associated with a 
premature cellular senescence of chondrocytes [11]. Indeed, 
OA chondrocytes express a panel of senescence markers 
including acidic -galactosidase activity [12], increase in 
reactive oxygen species (ROS), telomere attrition [13] and 
p53/p16
ink4 accumulation [11]. Although the subject of 
debate, apoptotic chondrocytes have also been detected by 
tunnel assay in OA cartilage [14, 15]. Furthermore, an 
increased number of chondrocytes with altered phenotype 
and chondrocyte progenitors have also been found in OA 
cartilage [8, 16]. Finally, an increased number of 
hypertrophic chondrocytes, characterised by the expression 
of specific markers, such as collagen type X, alkaline 
phosphatase or runx2, is frequently observed [17]. In 
summary, OA is a multi-phenotypic complex disease where 
articular chondrocytes exhibit characteristics of stress-
induced senescence with altered phenotypes and impaired 
normal anabolic capacities [11]. 
NEOPLASIA PHYSIOPATHOLOGY 
  Preneoplasic and neoplasic lesions are common. Both types 
of lesions are located within a high proliferative tissue and they 
increase with age. They are the result of abnormal cell 
proliferation that exceeds the surrounding normal tissue. 
Physiologically, preneoplasia preceed neoplasia and both stages 
of lesion progression are hardly distinguishable. Neoplasia can 
remain benign or degenerate into tumour. Preneoplasia is 
induced  in vivo following viral infection, recurrent genotoxic 
insults such as ultra-violet (UV), metabolic oxidative stress or 
genetic predisposition [18]. Genetic and molecular events that 
initiate this dysplasia have been broadly documented for the last 
15 years. Indeed, these abnormal cells harbour an apparent 
attempt to hyperproliferate but rather are kept confined by a 
permanent cell cycle arrest associated with a senescent 
phenotype and impaired secretor activities [5, 19-21]. 
SIMILARITIES BETWEEN OA- AND PRENEOPLASIA/ 
NEOPLASIA-ASSOCIATED MOLECULAR FACTORS 
  Cells are naturally exposed to various types of stress that 
lead to genomic assault during lifespan. Thus, cell-intrinsic 
mechanisms have evolved to limit the expansion of 
genetically altered cells. Cellular senescence is one of the 
natural barriers developed by multicellular organisms to 
suppress the unscheduled proliferation of damaged cells [19, 
22, 23]. Cellular senescence is therefore a strong tumour 
suppressor pathway that is activated in benign preneoplasic-
like lesions [5, 19, 21]. Remarkably, cellular senescence also 
occurs prematurely in OA chondrocytes. It is therefore 
tempting to make analogies between OA and preneoplasia 
associated characteristics (Fig. 1). 
ROS and Associated Cellular Senescence 
  Oxidative damage and the chronic production of 
endogenous ROS have been associated with aging in various  
 
human tissues and in animal models [24]. Articular 
chondrocytes actively produce ROS under mechanical stress 
or after inflammatory treatment [25, 26] and ROS secretion 
is believed to be one major mediator of OA-associated 
physiopathology [27]. Indeed, in vitro treatment of 
chondrocytes with oxygen peroxide (H2O2) used as source of 
ROS, resulted in p53/p21
Waf1/Cip1, p16
ink4a accumulation and 
telomere attrition which are both hallmarks of cellular 
senescence [12, 28, 29]. Furthermore, it has been reported 
that high level of ROS are produced by chondrocytes from 
OA patients [27, 30]. These molecular markers were also 
found in cartilage from patients with early OA suggesting 
their roles in the pathogenesis of the disease [11]. 
  Interestingly, ROS have been proposed to play a pivotal 
role in the genesis of preneoplasic tissues [4]. Indeed, 
treatment of cells with ROS or transduction of primary 
epithelial cells or fibroblasts with oncogenes inducing 
preneoplasia in vivo led to the rapid increase of intracellular 
ROS production [31]. ROS participated to the DNA damage 
accumulation and thereby to the activation of the DNA 
damage response (DDR) [4]. The DDR is the signalling 
pathway orchestrated by ATM/ATR kinases (Ataxia 
telangiectasia mutated and ATM-Rad3 related) transducing 
toward two checkpoint kinases namely Chk1/Chk2. The 
DDR converges to p53 and induces senescence-dependent 
cell cycle arrest characteristic of preneoplasic cells. 
Therefore, DDR activation induced by ROS accumulation is 
now believed to be the hallmark of in vivo senescent tissues 
[22, 32]. 
Inflammation and Pro-Inflammatory Cytokines 
  Although OA is classified as a non inflammatory disease, 
pro-inflammatory cytokines such as IL-1, TNF- or IL-8, 
have been reported to participate in OA physiopathology. 
Indeed, IL-1 and IL-8 were detected both in the synovial 
fluid and in cartilage from OA patients [33, 34]. Depending 
on cell culture conditions, IL-1-treated chondrocytes 
underwent either dedifferentiation or telomere dependent-
cellular senescence [29]. IL-8 has been proposed to induce 
chondrocyte hypertrophy and osteophyte formation which 
are observed in OA cartilage. Indeed, a time and dose-
dependent increase in the expression level of specific 
hypertrophic markers was observed in OA chondrocytes 
treated with IL-8 [35]. Nevertheless, the role of this cytokine 
remains unclear. 
  For decades, IL-1 and IL-8 are also associated with pre-
malignant and malignant tumour lesions [36]. These 
inflammatory cytokines together with IL-6 were recently 
shown to play a crucial role in the premature cellular 
senescence found in preneoplasic lesions [36-38]. Indeed, 
when over-expressed in primary fibroblasts, IL-8 and one of 
its known receptor, CXCR2 were sufficient to induce 
premature senescence (acidic -galactosidase staining and 
DDR activation) [38]. Furthermore, IL-8/CXCR2 tandem is 
transcriptionally induced by the DDR and participates to the 
senescence-dependent cell cycle arrest by producing more 
ROS [39]. Therefore, these signalling pathways including 
IL-8, IL-6 or Il-1 were postulated to be tumour suppressors 
with pro-aging properties and accordingly found activated in 
benign lesions and inactivated during tumour progression 
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IGFPB Family Members 
  Differential analysis of gene and protein expression in 
OA versus healthy age-matched chondrocytes has revealed 
the over-expression of members of the IGFBP family such as 
insulin growth factor binding protein (IGFBP)-3 and -7 [42, 
43]. IGFBP family members are pro-aging secreted factors 
known to modulate the insulin signalling pathway (for 
review, see [20]). Indeed, insulin pathway is central to aging 
and senescent mechanisms in modulating ROS production 
and cell survival [20, 44]. IGFBP-2/3 and -7 have also been 
shown to accumulate in preneoplasic-type lesions 
contributing to cellular senescence of these cells [3, 19, 45]. 
Vascularisation and VEGF Production 
  Another characteristic of OA cartilage is an increased 
expression level of vascular epithelial growth factor (VEGF). 
This growth factor is secreted by hypertrophic chondrocytes  
 
and contributes to vascularisation and attraction of cartilage-
resorbing cells during endochondral ossification in long bone 
development. In OA patients, VEGF production was shown 
to participate in the formation of osteophytes at the edges of 
articular cartilage [46]. However, the signalling pathways 
which control transcriptional induction of VEGF in OA 
chondrocytes are still being dissected. On the contrary, the 
transcriptional regulation and role of VEGF were broadly 
documented in early tumour development. Indeed, 
fibroblasts genetically modified to express oncogenes such 
as v-Ras or senescent fibroblasts were shown to secrete high 
levels of VEGF that can stimulate the proliferation of 
premalignant epithelial cells in culture and facilitate their 
conversion to malignant tambours in vivo [47]. This finding 
is believed to control the neo-vascularisation of neoplasic-
like tissues and tumour cell survival to hypoxia-induced 
apoptosis. 
 
 
Fig. (1). Cellular senescence is a common characteristic of preneoplasic tissue and cartilage in early osteoarthritis (OA). (A) Neoplasia 
genesis. Upon environmental stress (carcinogens, oncogenes, genotoxics), in highly proliferative tissues such as epithelium, some cells will 
respond by abortive proliferation and emergence of senescent cells. If one cell overcomes the senescent process by inactivation of the DNA 
damage response (DDR), cell proliferation will lead to neoplasia and eventually tumour. (B) OA genesis. Upon environmental stress 
(mechanical stress, aging factors), OA chondrocytes become senescent and display an imbalance between anabolic and catabolic activity in 
favour of catabolism, leading to cartilage degradation. In both tissues, common senescence-associated markers are expressed: activated DDR 
and secretion of reactive oxygen species (ROS), interleukin (IL)-1, IL-8, insulin growth factor binding protein (IGFBP)-3, vascular 
endothelial growth factor (VEGF) and metalloproteinases (MMPs). 
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Secretion of ECM Proteinases 
  Characteristic changes in early OA are similar to those 
seen with aging in cartilage from older, healthy subjects, 
with collagen damage and collagenases concentrated closer 
to the articular surface. Indeed, ECM degradation in OA was 
characterized by the secretion of metalloproteinases and 
aggrecanases such as MMP-1, -3, -8, -13 and a disintegrin 
and metalloproteinase with thrombospondin motif 
(ADAMTS)-5, respectively [48, 49]. Genetic inactivation of 
ADAMTS-5 prevented cartilage degeneration in OA-induced 
mice models [50, 51]. Recent studies revealed that senescent 
cells from preneoplasic tissues also promoted ECM 
degradation via the secretion of metalloproteinases such as 
MMP-3 [52]. The presence of metalloproteinases within 
preneoplasic lesions is believed to create a specific 
substratum which thereby facilitates the potential changes in 
cellular morphology required for tumour progression and 
metastasis [3]. 
CONCLUSIONS AND PERSPECTIVES 
  Cellular senescence seems to be a common process 
developed by OA chondrocytes and pre-tumour cells that 
may be at the genesis of both pathologies. Prevalence of 
these diseases increases with age and among the senescence-
associated markers, ROS accumulation plays a central role. 
ROS production induces DDR-dependent premature 
senescence in preneoplasic cells and in OA chondrocytes 
contributing to the loss of their anabolic functions. 
  A number of studies now suggest that senescent cells 
secrete specific factors that set the stage for a cross-talk 
between senescent cells and their environment [20]. Such 
signals would be integrated into a coordinated response that 
can cause other cell components to prematurely senesce 
thereby establishing a pro-aging loop [20]. The consequence 
of the pro-aging loop is the degradation of the ECM, 
degeneration of the targeted tissue and production of survival 
factors such as VEGF [37]. Indeed, OA chondrocytes and 
preneoplasic-associated senescent cells both secrete VEGF 
but in pre-tumour tissues, VEGF helps tissue growth and 
survival by promoting new blood vessel formation [47]. In 
contrast, in the cartilage, the increase in vascularisation 
participates to the aberrant ossification of cartilage leading to 
osteophyte formation [46]. This phenomenon would favour 
subchondral bone pressure in OA patients. 
  Two exciting points of view emerge from all the 
similarities reported here between both diseases. First, as we 
mentioned, the aetiology seems to be similar. In proliferative 
tissue such as epithelium, the accumulation of senescent 
cells within preneoplasic-like lesions harbouring specific 
secretary properties will lead to tissue degeneration and may 
induce tumour development [5, 20]. By chance, 
accumulation of premature senescent chondrocytes in OA 
lesions occurs in a slowly proliferative tissue, dramatically 
reducing the risk of cell transformation yet promoting tissue 
degeneration. Second, research on OA physiopathology 
should take into account the literature on the deciphering of 
the neoplasia-associated molecular mechanisms and the 
prevention of tumour formation. Indeed, according to the 
numerous similarities between preneoplasic and OA lesions, 
it would be questionable whether the battery of 
pharmaceutical compounds available for anti-cancer 
treatments such as anti-VEGF treatments could be tested by 
clinicians as potential OA treatments in order to delay or 
prevent the progression of this disease. 
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